Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.66 |
| ▸ | JAK2 | O60674 | 8/20 | 0.59 |
| ▸ | JAK1 | P23458 | 8/20 | 0.59 |
| ▸ | TYK2 | P29597 | 4/20 | 0.59 |
| ▸ | JAK3 | P52333 | 4/20 | 0.59 |
| ▸ | SYK | P43405 | 4/20 | 0.53 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24511502 | 0.95 | IRAK4 (0.67) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29664917 | 0.91 | IRAK4 (0.74) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29664729 | 0.87 | IRAK4 (0.79) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL24511493 | 0.87 | IRAK4 (0.79) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL24511601 | 0.80 | IRAK4 (0.58) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL358806 | 0.80 | IRAK4 (1.00) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL24511588 | 0.80 | IRAK4 (0.57) | IRAK4JAK2JAK1TYK2JAK3 | |
| SCHEMBL29664846 | 0.79 | MAPT (0.46) | IRAK4LMNA | |
| SCHEMBL24511648 | 0.79 | MAPT (0.46) | IRAK4LMNA | |
| SCHEMBL24511711 | 0.74 | IRAK4 (0.61) | IRAK4JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4259632-A1 | N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA | Astrazeneca AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022122876-A1 | N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |